Highlights
Pharmaceutical industry payments to neurologists significantly influence prescribing decisions for multiple sclerosis (MS) medications. Clinicians receiving $1,000 or more from brand-name drug manufacturers demonstrated substantially higher rates of prescribing expensive brand-name versions over available generics. This prescribing pattern carries profound implications for healthcare costs and patient access to affordable treatments.
